BCIQ Profiles

Company Profile ReportTarget Profile Report

AbbVie's elagolix meets in second Phase III for uterine fibroids

AbbVie Inc. (NYSE:ABBV) said elagolix (ABT-620) met the primary and all ranked secondary endpoints in the Phase III ELARIS UF-II (M12-817) trial, the second of two

Read the full 267 word article

How to gain access

Continue reading with a
two-week free trial.